Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Pharmacol Sci ; 148(4): 364-368, 2022 Apr.
Article in English | MEDLINE | ID: mdl-35300811

ABSTRACT

We examined whether galantamine (GAL), a cholinesterase inhibitor and allosteric potentiating ligand for α7 nicotinic acetylcholine receptor (nAChR), had an impact on emotional abnormalities in forebrain-specific cholecystokinin receptor-2 overexpressed transgenic mice. Treatment with GAL (1 mg/kg, s.c.) attenuated the decrease of social interaction time, but failed to attenuate anxiety-like behavior in the elevated plus-maze test. The effect of GAL was blocked by an α7 nAChR antagonist, methyllycaconitine (3 mg/kg, i.p.). These results suggest that GAL improved social interaction impairments via α7 nAChR and could be useful to treat sociability-related emotional abnormalities.


Subject(s)
Cholinesterase Inhibitors , Galantamine , Receptor, Cholecystokinin B , Social Behavior Disorders , Social Interaction , alpha7 Nicotinic Acetylcholine Receptor/antagonists & inhibitors , Animals , Cholinesterase Inhibitors/pharmacology , Cholinesterase Inhibitors/therapeutic use , Galantamine/pharmacology , Galantamine/therapeutic use , Mice , Receptor, Cholecystokinin B/genetics , Receptor, Cholecystokinin B/metabolism , Social Behavior Disorders/drug therapy , Social Interaction/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...